Phase 3 Readout
PVLA: Phase 3 Topline: SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN
July 1, 2026 · qtorin. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 1, 2026
- Company
- PALVELLA THERAPEUTICS, INC. (PVLA)
- Drug
- qtorin
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN
- Drug
- qtorin
- Indication
- Microcystic Lymphatic Malformation